Development of Oral Fomulation of SCV-07 for Use in Tuberculosis

Oak Ridge National Laboratory

关键词: Macrophages;    Tuberculosis;    Mycobacterium;    Lungs;    Cavities;   

DOI  :  10.2172/940308
RP-ID  :  ORNL03-0676
RP-ID  :  DE-AC05-00OR22725
RP-ID  :  940308

美国|英语

来源: UNT Digital Library

【 摘 要 】

An evaluation of the immunomodulatory peptide SCV-07 was conducted as a possible therapeutic treatment for tuberculosis. This evaluation included mouse models, clinical trials and various forms of the drug such as liquid injection and development of an oral pill. It was found that SCV-07 significantly increased the survival rate of animals infected with lethal doses of Mycobacterium bovis. It enhanced the functional activity of macrophages in a dose-dependent fashion. The combination of SCV-07 with bacteriostatic drugs, such as izoniazid, was particularly effective. Phase II clinical trials in a TB clinic demonstrated that the usage of the injection form of SCV-07 for lung TB treatment in combination with standard chemotherapy decreased the quantity of patients with positive sputum assays for Mycobacteria, promoted healing of cavities in lungs, stabilized parameters of cell immunity, and resulted in a significant improvement in the general condition of patients. Clinical trials results of the oral drug form are still being evaluated.